Cataract surgery remains one of the most successful and frequently performed procedures in medicine. Modern techniques, advanced intraocular lens (IOL) options, and highly accurate preoperative measurements have transformed outcomes for the vast majority of patients. In this context, the Light Adjustable Lens (LAL) is sometimes presented as a cutting-edge solution that allows postoperative fine-tuning of refractive power using ultraviolet light. While the technology is interesting, we do not routinely recommend or implant the LAL at this point at SHARPEVISION. After careful evaluation of its benefits, limitations, and practical realities, we have concluded that it is largely a solution looking for a problem for most patients.

It Is Not a Multifocal Lens

One of the primary reasons patients seek premium lens options is the desire for reduced dependence on glasses for both distance and near vision. Multifocal and extended-depth-of-focus IOLs are specifically designed to provide a range of vision. The LAL, by contrast, is a monofocal adjustable lens. It can be fine-tuned for a precise distance or intermediate target, but it does not inherently deliver the simultaneous near and distance performance that many patients expect from advanced-technology lenses. Patients who choose the LAL still typically require reading glasses for near tasks, just as they would with a standard monofocal IOL. For individuals whose primary goal is spectacle independence across multiple distances, the LAL does not address that need.

Stability Is Not Guaranteed

Although the LAL is marketed for its adjustability, refractive stability after the adjustment and lock-in process is not absolute. Some patients experience residual refractive shifts even after the recommended light treatments. Factors such as healing response, capsular bag contraction, and individual biological variability can influence the final result. In practice, this means the promised precision does not always translate into a perfectly stable outcome. When instability occurs, the patient may still need glasses or further intervention, undermining one of the main purported advantages of the technology.

Multiple Visits and Lock-In Treatments Are Required

The LAL workflow demands a series of postoperative visits that extend well beyond the typical cataract surgery recovery schedule. After implantation, patients must return for refractive assessment, undergo one or more ultraviolet light adjustment sessions, and then complete additional “lock-in” treatments to permanently set the lens power. These appointments require time, transportation, and careful adherence to UV-protective eyewear protocols between visits. For many patients—especially those who travel, work, or have mobility limitations—the added burden is significant. Standard monofocal or premium IOLs, by comparison, usually involve far fewer postoperative visits and do not require specialized light treatments or prolonged UV precautions.

Removal, If Ever Needed, Is Technically Challenging

Although IOL exchange is uncommon, it occasionally becomes necessary due to refractive surprise, dissatisfaction, or rare complications. The LAL presents particular difficulties in this scenario. The lens is larger than many conventional IOLs and has a unique material composition that can fragment into multiple pieces during explantation. Removing a fragmented LAL increases surgical time, complexity, and risk to the eye. In contrast, most modern non-adjustable lenses can be removed more straightforwardly when exchange is required. This difference in revisability is an important consideration when selecting an implant that will remain in the eye for decades.

Excellent Biometry Makes Adjustability Unnecessary for Most Patients

Perhaps the strongest argument against routine use of the LAL is the remarkable accuracy of contemporary lens calculation. Advanced biometry devices, refined formulas, and careful surgical technique now deliver refractive outcomes within the desired target in approximately 98% of routine cataract cases. At SharpeVision, we use the latest swept source ocular biometry device, the Argos, by Alcon. Residual refractive error, when it occurs, is usually small. For the large majority of patients, a well-chosen non-adjustable lens provides an excellent result without the added complexity, cost, and follow-up demands of an adjustable platform. Investing in adjustability for a problem that arises only rarely is inefficient and mostly unnecessary.

We Already Offer a Reliable, No-Cost Refractive Touch-Up Option

At SHARPEVISION, patients who select premium lenses receive an important safeguard: if a meaningful refractive residual remains after surgery, we can, but infrequently need to perform a laser vision correction enhancement at no additional charge. This approach allows us to fine-tune the final outcome with a mature, widely studied technology (LASIK or PRK) that does not require special lens materials or multiple lock-in visits. The laser enhancement pathway is flexible, effective, and integrated into our existing postoperative care. It addresses the occasional residual refractive error without committing every patient to the LAL protocol.

Limited Situations Where the LAL May Be Considered

We acknowledge that the LAL can be useful in a narrow subset of eyes. Patients with prior radial keratotomy (RK), corneal transplants, significant corneal scars, or other irregular corneal surfaces sometimes present measurement challenges that reduce the predictability of standard IOL calculations. In these uncommon situations, the ability to adjust power after the eye has healed can provide a valuable safety net. Even then, the decision is individualized and made only after thorough discussion of the added visits, UV precautions, and potential explantation difficulties. For the typical cataract patient with a regular cornea and accurate biometry, these advantages do not apply.

A Solution Looking for a Problem

Technology should solve real clinical problems, not create new logistical and surgical ones. The LAL offers postoperative adjustability, yet modern biometry already delivers highly predictable results for nearly all patients. It requires a more intensive follow-up regimen, lacks multifocal capability, carries greater difficulty if removal is ever needed, and is not guaranteed to remain perfectly stable. Meanwhile, we already possess an effective laser option to refine outcomes when necessary—at no extra cost for premium-lens patients. Taken together, these factors lead us to view the LAL as a solution looking for a problem in the great majority of cases.

Our philosophy prioritizes proven outcomes, patient convenience, surgical revisability, and appropriate use of resources. We continue to monitor advances in adjustable-lens technology and will reconsider our stance if future iterations meaningfully improve stability, reduce the visit burden, enhance multifocal performance, or simplify explantation. Until then, we prefer to reserve the LAL for the small percentage of eyes with genuinely unpredictable optics and to rely on excellent biometry, carefully selected non-adjustable lenses, and selective laser enhancement for everyone else. This approach consistently delivers the clear, stable vision our patients expect with the fewest unnecessary steps along the way.

In summary, while the Light Adjustable Lens represents an innovative concept, its practical limitations and the excellence of current standard techniques make it unnecessary for most cataract surgery patients. At SHARPEVISION, we have been, and always will be committed to offering the safest, most effective, and most patient-friendly options available—options that already achieve outstanding results without the added complexity of postoperative light adjustments and lock-in treatments.